Free Trial

Pittenger & Anderson Inc. Reduces Stock Position in Danaher Corporation (NYSE:DHR)

Danaher logo with Medical background

Pittenger & Anderson Inc. trimmed its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 48.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,528 shares of the conglomerate's stock after selling 32,770 shares during the quarter. Pittenger & Anderson Inc.'s holdings in Danaher were worth $7,283,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. GHP Investment Advisors Inc. increased its stake in Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares in the last quarter. Heck Capital Advisors LLC bought a new stake in Danaher during the 4th quarter valued at $27,000. Sierra Ocean LLC increased its stake in Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after purchasing an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC bought a new stake in shares of Danaher in the 1st quarter worth $31,000. Finally, Hurley Capital LLC bought a new stake in shares of Danaher in the 4th quarter worth $34,000. 79.05% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president directly owned 15,179 shares of the company's stock, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the sale, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.10% of the company's stock.

Danaher Price Performance

Shares of Danaher stock traded down $0.71 on Friday, reaching $204.80. The stock had a trading volume of 2,369,010 shares, compared to its average volume of 3,508,130. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $281.70. The company has a market cap of $146.57 billion, a P/E ratio of 39.77, a price-to-earnings-growth ratio of 2.88 and a beta of 0.77. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The business's 50 day moving average is $196.05 and its two-hundred day moving average is $206.30.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. As a group, research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.63%. Danaher's dividend payout ratio is currently 24.85%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on DHR. Argus reduced their target price on shares of Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Robert W. Baird reduced their target price on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating for the company in a research note on Wednesday, April 23rd. Jefferies Financial Group reduced their target price on shares of Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a research note on Tuesday, April 22nd. HSBC reduced their target price on shares of Danaher from $270.00 to $240.00 in a research note on Friday, April 25th. Finally, Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $248.43.

View Our Latest Report on DHR

Danaher Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

See Also

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Watch Before Monday: Stocks to Load Up on Before Earnings
3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines